CD4 and hepatitis C virus infection: For hepatitis A screening, we found that 4 out of the 5 sites that showed a significant increase in their raw rate at 12 months, also showed a significant increase in their raw rate at 24 months compared to baseline (p = .05). For the other four significant indicators of HIVGBC (hepatitis C and toxoplasma screening, CD4/viral load and lipids monitoring), all sites that showed significant increases in their raw performance rates at 12 months, showed a significant increase in their raw rates at 24 months compared to baseline.